Have you implemented circulating tumor DNA (ctDNA) monitoring in your practice? Join our educational webinar to learn about how ctDNA-based treatment response monitoring (TRM) can provide objective insights into a patient’s response. 🔗 to register: bit.ly/40pI9Gq

Just published Clinical Cancer Research Is it a myth🐉that you can’t detect fusions on #ctDNA? 👇🏾Presenting one of the largest datasets on #LiquidBiopsies & Fusion🖇️detection 53,842 patients 1️⃣4️⃣% had a pathogenic rearrangement detected Shedding💦matters OncoAlert aacrjournals.org/clincancerres/…

A call to action to advance patient-focused and decentralized clinical trials. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… ACS Research ACS Journal Cancer R. Donald Harvey PharmD @ME_Fleury #CancerResearch #ClinicalTrials

Get ready for Session: Exploring the Clinical Utility of Dynamic #ctDNA Monitoring at #PMWC24. Join Lincoln Pasquina Foundation Medicine, Hatim Husain UC San Diego Health on 2024-01-24, Track: 3, 1.45 P.M. More at: pmwcintl.com/program

🚨 In International Society of Liquid Biopsy journal "Putting comprehensive 🧬 profiling of ctDNA to work" We explore ctDNA's utility across 4 categories: 1️⃣ Established 💊 selection 2️⃣ Emerging 3️⃣ Incidental discovery of secondary genomic findings 4️⃣ Quantification bit.ly/42bvXKp

Liquid Biopsy (LBx) of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment. Our analysis of a large database further reinforce the clinical utility of early LBx use in pts with suspected lung cancer. Christian Rolfo Geoff Oxnard MD Lincoln Pasquina

Just out in ESMO RWD: ctDNA tumor fraction from Foundation Medicine F1LCDx is associated with rwPFS and is prognostic across a range of TF cut points in metastatic urothelial carcinoma. With Ben Miron Shilpa Gupta Ryon Graf, PhD Geoff Oxnard MD esmorwd.org/article/S2949-…

Newly #Published in the Journal of Liquid Biopsy – “Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases.” Read this piece of #research at the link: bit.ly/4ccWz2f

A seminal paper in the liquid biopsy field by Christian Rolfo and colleagues. ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. Clinical Cancer Research International Society of Liquid Biopsy Foundation Medicine aacrjournals.org/clincancerres/…

.Christian Rolfo et al. demonstrate that early liquid biopsy in aNSCLC in parallel with path dx is associated with shorter time to treatment: brnw.ch/21wIgRk #LCSM

#NewStudy in Clinical Cancer Research evaluates circulating tumor DNA tumor fraction, a determination of ctDNA in liquid biopsy samples from Foundation Medicine’s blood-based comprehensive genomic profiling test, for its utility in identifying true negative results: bit.ly/43IMS7V

Clinical Cancer Research Excited to share this new research in collaboration with Christian Rolfo et al. For more details on this research, click here: bit.ly/43IMS7V

Liquid biopsy in head and neck cancers? Let's discuss at #AACR2024!

Open now – a Call for Grants Notification, seeking collaborative projects & initiatives to address disparities in underserved breast or prostate cancer populations in the United States. Interested in applying? Click the link for more information: bit.ly/3vPlIjg

Thanks to ESMO - Eur. Oncology ESMO Daily for highlighting our paper in Clinical Cancer Research Tumor Fraction #liquidbiopsy. This is an important concept to distinguish non shedders to non informative LB. Lincoln Pasquina Hatim Husain The Tisch Cancer Institute Great comment by Umberto Malapelle dailyreporter.esmo.org/news/liquid-bi…

🚨Thanks ⁦⁦Dr Rafeq Naqash Rafeh Naqash, MD⁩ for the kind invitation to ⁦JCO Precision Oncology⁩ conversations podcast 🎤on our paper📝“Liquid Biopsy of Lung Cancer Before Path Diagnosis”⁦⁩ ⁦Alessandro Russo⁩ ⁦Lincoln Pasquina⁩ ⁦ASCO⁩ sites.libsyn.com/427415/liquid-…

Thanks Rafeh Naqash, MD & JCO Precision Oncology for the kind interview on our paper and great conversation! International Society of Liquid Biopsy The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Alessandro Russo Marzia Del Re, PharmD, PhD Geoff Oxnard MD Lincoln Pasquina OncoAlert The ASCO Post ASCO

Meet us in Chicago! Find us at Booth 22031 to learn more about Foundation Medicine’s high-quality tests and our work in precision cancer care: bit.ly/44UHCib #ASCO24

Had a fun time presenting our poster at #ASCO2024 on #ctDNA in pts with #mHSPC! Thanks to our pts, mentor Zachery Reichert, MD, PhD, and Todd 〽️ Morgan, MD lab as well as Foundation Medicine for the collaboration! Lincoln Pasquina Ryon Graf, PhD GU Oncology Now Uromigos UroToday.com U-M Rogel Cancer Center

We’re in Chicago for #ASCO25 – come visit us at booth 27021 to learn more about Foundation Medicine. Schedule a meeting with us today: spkl.io/6014ffdmC #MissNotOne